iTeos Therapeutics, Inc.

Relations at ITOS. Please proceed.

Thank you for joining us today. Joining me from ITOS with prepared remarks are Michelle Dittou, President and CEO, and Matthew Gall, Chief Financial Officer. Dr. Joanne Lager, Chief Medical Officer, will be available for Q&A. Before we begin, I would like to remind you all that the team will be making forward-looking statements in the prepared remarks and during the Q&A sessions. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that such forward-looking statements reflect our current expectations and assumptions regarding timing, progress, and success of our current ongoing clinical trials, therapeutic potential thereof, expected milestones, our financial condition, including cash runway, our business operation, development efforts, and relationships with third parties and collaborators, and are neither predictions nor guarantees of future events or performance. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business, including those under the heading entitled Risk Factors in our quarterly report on Form 10-Q for the quarter ended June 30, 2021, which was filed yesterday with the SEC, as well as in subsequent reports, including our current reports on Form 8-K. The company disclaims any obligation to update or revise any forward-looking statements except as required by law. Michel?

Thank you very much, Ryan. Good morning, good afternoon, everyone. I would like to begin today's call by reflecting on the substantial progress we have made at ITOS and the recent announcement of our strategic partnership with Lexos Mclaren for our potent high affinity anti-tigit antibody EOS-448. This partnership brings value to ITOS, not only giving this program best in class resources, for clinical development now and as we look forward for both commercialization, but also validating our scientific approach and rigor. It also provides a catalyst for our talented team to continue to grow our pipeline of highly differentiated immunology therapeutics. Our team is deeply committed to developing therapies that focus on mechanisms of immunosuppression. Our approach involves targeting the pathway to reduce immunosuppression and restore the immune response against cancer, meeting the high unmet need that remains for cancer patients. In the last four years, we have put three distinct and highly differentiated programs into clinical trials And with the strategy course of significant value creation, we have shown that we can leverage our expertise in tumor genealogy and continue to build a robust pipeline going forward. Before I go into more detail on EOS-448 impediment and on our plan to further grow our pipeline, let me just take a moment to summarize our partnership with GlaxoSmithKline. We selected GSK as our partner for EOS 448 as there is a strategic focus on the TIGIT CD226 axis, and they share our belief that combination of PD-1, TIGIT, CD96, and CD112 receptor inhibitor can transform cancer care for the mini-patient who lacks effective treatment options. The deal recently closed, and as a result, we received a $625 million upfront payment. We will be eligible to receive up to an additional $1.45 billion in milestones payments should the EOS 448 program achieve certain development and commercial milestones. GSK and ITOs will share responsibility and cost with a 60-40 ratio, respectively, for the global development of EOS 448, and will jointly commercialize and equally split profits in the U.S. Outside of the U.S., GSK will receive an exclusive license for commercialization, and ICOs will receive tiered royalty payments. These attributes, both in a partner and in structure, will allow us to expand and accelerate the development of EOS 448 and meaningfully participate in the development process, commercialization, and in the value created. We could not be more happier to be working with a partner with the capabilities and portfolio of GSK, and we leverage this collaboration to generate significant value for all our stakeholders. EOS448 has the potential to achieve significant immune stimulatory effects through three mechanisms. One, docking the binding of STIGIT with LIGN, presenting an immune-mediated killing of tumor cells by T cells and NK cells. Two, engaging the S-C gamma receptor to further promote anti-tumor immune response in dendritic cells and macrophage. through the release of pro-inflammatory cytokines and chemokines, and the activation of antigen-presenting cells. And three, activating NK cells and macrophage to defeat TG-positive cells that are known to dampen the immune response, like immunosuppressive Tregs and exhausted T cells. We are highly encouraging initial sourcing human data for EOS448 and are pleased therapy in advanced solid tumor during our phase one. Data presented at ACR in April showed that out of 20 patients treated with single-agent US448, half of the patients had stable disease or better, and there was a confirmed partial response in a patient with panprolizumab-resistant melanoma. Peripheral biomarker data concern deposition of TGIT-positive Treg cells and reduction in exhausted TGIT-positive CDA T cells, whereas the other receptor T cells remain unchanged, demonstrating a multifaceted mechanism based on potent engagement of both TGIT and the S-sigma receptor by EOS44A. Based on the robust biomarker data, Preliminary signs of efficacy as monotherapy and data showing EOS448 was well-tolerated with no dose-limiting toxicities, the clinical development plan with GSK is geared towards advancing rapidly to registration-directed trials in indication and combination where we see the most potential to benefit patients. Having a partner with an approved PD-1 and a portfolio of potentially complementary programs gives us the ability to move rapidly towards approval and to work with GSK on novel regiments. We plan to start combination studies of EOS-448 with GSK recently approved anti-PD-1 drug, Janperli, or Dostarlimab, later this year, and plan to initiate trials in non-small cell-line cancer and additional indication in 2022. We are currently initiating a trial of EOS-448 in combination with Pembrolizumab and with our novel A2A receptor antagonist, Inepadinant, in patients with solid tumor. We are also moving forward with a trial to evaluate US448 as a monotherapy and in combination with a imid molecule in patients with multiple myeloma. Turning to imipadenone, adenosine suppress the immune response against tumor and inhibit responses to current cancer therapies. The adenosine receptor, A2L receptor, is a routine receptor responsible for mediating adenosine in a suppressive effect on immune cells within the tumor. Based on our understanding of the unique condition within the tumor microenvironment, we thoughtfully designed inopadenone, a drug that could selectively and potently inhibit A2A receptor, even in the high concentration of adenosine in the tumor microenvironment. Inopadinone is a next-generation A2A receptor antagonist with differentiated pharmacologic properties. Unlike prior generation of adenosine receptor antagonists, Inopadinone was designed to inhibit A2A receptor even at high concentration of adenosine. Inipazinone is highly selective for A2A receptor and has no brain penetration properties which are expected to reduce off-target safety effects and improve the therapeutic index. At ASCO in June, we reported updated results from our monotherapy dose exfoliation phase 1 to S30. In 43 patients with advanced solid tumor treated with single-agent inipazinone, We saw durable responses of stable disease greater than six months in five patients with advanced solid tumor, including the previously reported confirmed partial response in patients with checkpoint inhibitor-resistant melanoma and heavily pretreated castrate-resistant prostate cancer. Both of these responses have lasted greater than 12 months. We also newly reported a patient with non-small cell and cancer with stable disease lasting for more than 10 months. We are pleased with the best and durability of the antitumor responses we have observed today and with the tolerability of . Preliminary analysis of tumor biopsies indicated that the expression of A2A receptor in pre-treatment tumor samples is associated with clinical outcomes in patients with solid tumor treated with single-agent independent. We will continue to integrate a biomarker-driven approach into our A2L receptor clinical programs to choose optimal therapeutic combination and identify the patient most likely to benefit from treatment. We are currently evaluating in combination with pembrolizumab and with chemotherapy, and we are planning expansion in selected three tumors, including PD-1-resistant melanoma and another large indication, and we will continue to evaluate potential biomarkers. More information about our complete development plan will be shared in the near future. We will also be initiating evaluation of a triple combination of inipalinin, EOS-448, and PD-1. Turning to our discovery engine, we have a robust discovery effort ongoing, and we continue to possess research programs focused on additional targets that address pathways of immunosuppression. As we build our pipeline, we expect to nominate an additional product candidate for IND-enabling studies before the end of 2021. The team is very excited about this candidate, which targets an internally discovered mechanism of immunosuppression in the NLV pathway, and which we believe will be a 13-class agent. We believe that we have assembled significant expertise in target identification, modality selection, and that we can leverage to build upon our demonstrated of success to build a differentiated IO pipeline. With our headquarters in Cambridge, Massachusetts, and our R&D center in Belgium, IT as global presence allows us to attract talent worldwide and remain at the forefront of innovation in the field of immunology. I will now hand the call over to Mathieu Holl, our Chief Financial Officer. Thanks, Michel.